After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
The company's hepatitis C drug division is expected to see losses in the second half of the year.
Some of this month's most explosive moves are coming from large-cap stocks. Here's how to profit from five of them.
It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.
There were many earnings reports today, and many could've been worse, Cramer says.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.